Piperacillin/tazobactam vs. cefoperazone/sulbactam in adult low-risk febrile neutropenia cases
Author:
Affiliation:
1. Department of Infectious Diseases and Clinical Microbiology; Faculty of Medicine; Ege University; Izmir Turkey
2. Urla State Hospital; Izmir Turkey
3. Bornova Public Health Center; Izmir Turkey
Publisher
Hindawi Limited
Subject
General Medicine
Reference18 articles.
1. Guidelines for diagnosis and treatment of neutropenic patients;Febrile Neutropenia Study Group;Flora,2004
2. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America;Freifeld;Clin Infect Dis,2011
3. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why monotherapy?;Williams;J Antimicrob Chemother,2009
4. Imipenem-cilastatin versus sulbactam cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients;Ozyilkan;Korean J Intern Med,1999
5. Imipenem or cefoperazone sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients;Bodey;Eur J Clin Microbiol Infect Dis,1996
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The clinical features, treatment and prognosis of neutropenic fever and Coronavirus disease 2019 results of the multicentre teos study;Scientific Reports;2024-03-03
2. Use of cefepime, meropenem, or piperacillin/tazobactam as initial treatment for febrile neutropenia in patients with hematological malignancy — a real-life experience;The Egyptian Journal of Internal Medicine;2022-08-19
3. Commentary on Cefepime versus Cefoperazone/Sulbactam in Combination with Amikacin as Empirical Antibiotic Therapy in Febrile Neutropenia;Indian Journal of Medical and Paediatric Oncology;2020-07
4. The cost-effectiveness of empirical antibiotic treatments for high-risk febrile neutropenic patients;Medicine;2020-05-15
5. Efficacy and safety of cefoperazone-sulbactam in empiric therapy for febrile neutropenia;Medicine;2020-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3